[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201991618A1 - Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения - Google Patents

Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения

Info

Publication number
EA201991618A1
EA201991618A1 EA201991618A EA201991618A EA201991618A1 EA 201991618 A1 EA201991618 A1 EA 201991618A1 EA 201991618 A EA201991618 A EA 201991618A EA 201991618 A EA201991618 A EA 201991618A EA 201991618 A1 EA201991618 A1 EA 201991618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
salt
tebipenem pivoxil
pivoxil
methods
crystalline
Prior art date
Application number
EA201991618A
Other languages
English (en)
Inventor
Акаш Джейн
Эван Хекер
Ричард Эдвардс
Тьерри Бонно
Original Assignee
Сперо Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сперо Терапьютикс, Инк. filed Critical Сперо Терапьютикс, Инк.
Publication of EA201991618A1 publication Critical patent/EA201991618A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на новые кристаллические солевые формы тебипенема пивоксила, включая кристаллическую солевую форму этансульфоната тебипенема пивоксила (форму A), кристаллическую солевую форму кетоглутарата тебипенема пивоксила (форму A), солевые формы малеата тебипенема пивоксила (формы A и B), солевую форму малата тебипенема пивоксила (форму A), солевую форму метансульфоната тебипенема пивоксила (форму B), солевую форму гидробромида тебипенема пивоксила (форму B) и солевую форму эдизилата тебипенема пивоксила (форму A). Настоящее изобретение также включает композицию, содержащую кристаллическую соль тебипенема пивоксила и фармацевтически приемлемый носитель, и дополнительно включает способ лечения устойчивой к действию антибиотиков бактериальной инфекции, включающий введение пациенту, нуждающемуся в таком лечении, терапевтически эффективного количества кристаллической соли тебипенема пивоксила.
EA201991618A 2017-02-06 2018-02-06 Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения EA201991618A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762455109P 2017-02-06 2017-02-06
PCT/US2018/017067 WO2018145089A1 (en) 2017-02-06 2018-02-06 Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

Publications (1)

Publication Number Publication Date
EA201991618A1 true EA201991618A1 (ru) 2020-01-30

Family

ID=61244766

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991618A EA201991618A1 (ru) 2017-02-06 2018-02-06 Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения

Country Status (16)

Country Link
US (3) US10889587B2 (ru)
EP (1) EP3577119A1 (ru)
JP (1) JP7309607B2 (ru)
KR (1) KR102608037B1 (ru)
CN (2) CN110234651A (ru)
AU (2) AU2018215687B2 (ru)
BR (1) BR112019015487A2 (ru)
CA (1) CA3049690C (ru)
CO (1) CO2019007879A2 (ru)
EA (1) EA201991618A1 (ru)
IL (1) IL268092B2 (ru)
MX (1) MX2019009288A (ru)
NZ (1) NZ753781A (ru)
PH (1) PH12019501245A1 (ru)
WO (1) WO2018145089A1 (ru)
ZA (2) ZA201903310B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102608037B1 (ko) 2017-02-06 2023-11-30 스페로 테라퓨틱스, 인코퍼레이티드 테비페넴 피복실 결정질 형태, 이를 포함하는 조성물, 제조 방법, 및 사용 방법
CN110804057A (zh) * 2019-11-11 2020-02-18 浙江海翔药业股份有限公司 替比培南酯氢溴酸盐晶型及其制备方法、药物组合物和制药用途
CA3201497A1 (en) * 2020-11-11 2022-05-19 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
CN112812116A (zh) * 2020-12-31 2021-05-18 山东华鲁制药有限公司 一种药用替比培南匹伏酯的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU682510B2 (en) * 1993-07-01 1997-10-09 Pfizer Japan Inc. 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thio-carbapenem derivatives
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JP3317604B2 (ja) 1994-12-28 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
TW420681B (en) 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
JP3317649B2 (ja) * 1997-01-13 2002-08-26 日本ワイスレダリー株式会社 結晶形態のカルバペネム化合物
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
KR100950699B1 (ko) * 2008-03-28 2010-03-31 국제약품공업주식회사 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르유도체의 산부가염, 이의 제조방법 및 이를 포함하는 약학조성물
WO2009066917A2 (en) 2007-11-23 2009-05-28 Kukje Pharm. Ind. Co., Ltd. 2-arylmethylazetidine-carbapenem-3-carboxylic acid ester derivative or its salt, process for the preparation thereof and pharmaceutical composition comprising the same
KR100930586B1 (ko) * 2007-11-23 2009-12-09 한국화학연구원 2-아릴메틸아제티딘-카바페넴-3-카복실산 에스테르 유도체,이의 제조방법 및 이를 포함하는 약학 조성물
CN102558181B (zh) 2010-12-15 2015-04-22 石药集团中奇制药技术（石家庄）有限公司 一种碳青霉烯抗生素的制备方法
CN102731507B (zh) 2011-04-13 2015-04-01 石药集团中奇制药技术（石家庄）有限公司 泰比培南晶型、其制备方法及其在制备药物中的应用
CN102276611B (zh) 2011-05-18 2013-01-09 深圳万乐药业有限公司 一种替比培南酯的重结晶精制方法
CN103664948B (zh) 2012-09-05 2015-12-16 凌沛学 一种替比培南酯的中间体的结晶及其制备方法
CN103664949A (zh) 2012-09-12 2014-03-26 高瑞耀业(北京)科技有限公司 替比培南匹伏酯结晶及其制备方法
CN106543186A (zh) 2016-11-07 2017-03-29 山东大学 一种替比培南匹伏酯的单晶a及其制备方法
US20200016126A1 (en) * 2016-12-15 2020-01-16 Spero Therapeutics, Inc. Novel tebipenem pivoxil immediate and modified release oral dosage forms
KR102608037B1 (ko) 2017-02-06 2023-11-30 스페로 테라퓨틱스, 인코퍼레이티드 테비페넴 피복실 결정질 형태, 이를 포함하는 조성물, 제조 방법, 및 사용 방법
CN108640920B (zh) 2018-04-03 2020-03-27 科兴生物制药股份有限公司 一种替比培南酯的制备方法
CN109096283A (zh) 2018-09-03 2018-12-28 成都倍特药业有限公司 一种高纯度替比培南酯晶体的制备方法
CN109651372A (zh) 2018-12-27 2019-04-19 开封制药(集团)有限公司 一种替比培南酸的制备方法

Also Published As

Publication number Publication date
CN117551102A (zh) 2024-02-13
JP2020506196A (ja) 2020-02-27
AU2018215687A1 (en) 2019-06-13
AU2020281120A1 (en) 2021-01-07
CA3049690C (en) 2023-03-21
IL268092A (en) 2019-09-26
MX2019009288A (es) 2019-09-10
US20210122753A1 (en) 2021-04-29
BR112019015487A2 (pt) 2020-03-31
ZA202103498B (en) 2023-01-25
US12098155B2 (en) 2024-09-24
US20230331728A1 (en) 2023-10-19
CO2019007879A2 (es) 2019-07-31
IL268092B (en) 2022-10-01
US20200055857A1 (en) 2020-02-20
EP3577119A1 (en) 2019-12-11
US10889587B2 (en) 2021-01-12
US11718621B2 (en) 2023-08-08
KR102608037B1 (ko) 2023-11-30
ZA201903310B (en) 2021-09-29
IL268092B2 (en) 2023-02-01
PH12019501245A1 (en) 2020-03-02
CA3049690A1 (en) 2018-08-09
JP7309607B2 (ja) 2023-07-18
CN110234651A (zh) 2019-09-13
AU2018215687B2 (en) 2020-09-03
NZ753781A (en) 2022-10-28
KR20190115000A (ko) 2019-10-10
WO2018145089A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
EA202090604A1 (ru) Хроманмонобактамовые соединения для лечения бактериальных инфекций
EA201991618A1 (ru) Кристаллические формы тебипенема пивоксила, композиции, содержащие их, способы изготовления и способы применения
JOP20190257A1 (ar) مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
EA200970535A1 (ru) Антибактериальные производные хинолина
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
PH12020550452A1 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
EA202191239A1 (ru) Соединения и их применение для лечения дефицита 1-антитрипсина
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022000143A (es) Metodos novedosos.
MX2019010695A (es) Compuesto antimicrobiano ((2r,3s,5r)-5-(4-amino-2-oxopirimidin-1(2 h)- il)-3-((butoxióxidofosfor-il)oxi) tetrahidrofuran-2-il)metil butil fosfato, y el uso del mismo en infecciones.
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
SA521431048B1 (ar) مركبات بيروليدين
EA201491982A1 (ru) Антибактериальные хинолиновые производные
MX2024005453A (es) Composiciones y tratamientos con nirogacestat.
MX2019006768A (es) Peptidos antimicrobianos.
PH12019502510A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
MX2021011986A (es) Metodos de tratamiento de dolor neuropatico.
EA200970536A1 (ru) Антибактериальные хинолиновые производные
PH12020551117A1 (en) Compositions for preventing or treating uveitis
EA201491971A1 (ru) Антибактериальные хинолиновые производные
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
EA202193211A1 (ru) Лечение синуклеопатий